This compound is a steroidal intermediate used in the synthesis of Fulvestrant, a pharmaceutical agent. It features a complex polycyclic structure with a long alkyl side chain containing both sulfur and multiple fluorine atoms, contributing to its high lipophilicity.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
(7R,8R,9S,10R,13S,14S,17S)-7-(9-Bromononyl)-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
research compound
(7a,17b)-7-(9-Bromononyl)-estra-1,3,5(10)-triene-3,17-diol 17-acetate
pharmaceutical intermediate
(7a,17b)-7-(9-Bromononyl)estra-1,3,5(10)-triene-3,17-diol
pharmaceutical intermediate
(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonyl]-estra-1,3,5(10)-triene-3,17-diol
pharmaceutical intermediate
Dimethylmethoxy chromanol
pharmaceutical intermediate
4-bromo-2-fluorobiphenyl
pharmaceutical intermediate
Allopurinol Impurity 9
pharmaceutical intermediate
Beta-D-Galactose pentaacetate
pharmaceutical intermediate
[(7R,8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-7-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
VAFUQFCTCUWBQD-YPTRIRRJSA-N
CC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](CC4=CC(=O)CC[C@H]34)CCCCCCCCCSCCCC(C(F)(F)F)(F)F)C
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.